<code id='BDB44A9861'></code><style id='BDB44A9861'></style>
    • <acronym id='BDB44A9861'></acronym>
      <center id='BDB44A9861'><center id='BDB44A9861'><tfoot id='BDB44A9861'></tfoot></center><abbr id='BDB44A9861'><dir id='BDB44A9861'><tfoot id='BDB44A9861'></tfoot><noframes id='BDB44A9861'>

    • <optgroup id='BDB44A9861'><strike id='BDB44A9861'><sup id='BDB44A9861'></sup></strike><code id='BDB44A9861'></code></optgroup>
        1. <b id='BDB44A9861'><label id='BDB44A9861'><select id='BDB44A9861'><dt id='BDB44A9861'><span id='BDB44A9861'></span></dt></select></label></b><u id='BDB44A9861'></u>
          <i id='BDB44A9861'><strike id='BDB44A9861'><tt id='BDB44A9861'><pre id='BDB44A9861'></pre></tt></strike></i>

          
          WSS
          3d heart myocarditis
          Adobe

          A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

          The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

          advertisement

          In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion